Welcome to our dedicated page for Scholar Rock Holding SEC filings (Ticker: SRRK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Scholar Rock Holding Corporation (SRRK) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a Nasdaq-listed biopharmaceutical issuer. Scholar Rock files reports and current updates with the U.S. Securities and Exchange Commission (SEC) that describe its financial condition, clinical and regulatory milestones, capital markets activity, and material corporate events.
For SRRK, Form 8-K current reports are particularly important. Recent 8-K filings have covered quarterly financial and operating results, conference call presentations, and key regulatory developments such as the U.S. Food and Drug Administration’s Complete Response Letter (CRL) for the apitegromab Biologics License Application (BLA) in spinal muscular atrophy (SMA). Other 8-Ks describe the inspection status of a third-party fill-finish facility, the use of an at-the-market equity offering program with Jefferies LLC, and the filing of a prospectus supplement for additional common stock issuance.
Scholar Rock’s filings also document its status as a registrant on The Nasdaq Global Select Market under the ticker SRRK, the terms of its common stock, and its use of a shelf registration statement on Form S-3ASR. Inducement equity awards granted under the company’s 2022 Inducement Equity Plan are reflected in press releases that may be furnished as exhibits to 8-Ks, providing detail on stock options and restricted stock units granted to new employees.
On Stock Titan, users can review these SEC documents alongside AI-powered summaries that explain the main points of each filing in accessible language. Real-time updates from EDGAR help surface new 8-Ks, 10-Q quarterly reports, 10-K annual reports, and any future registration statements or prospectus supplements related to Scholar Rock’s capital-raising activities. For investors analyzing SRRK’s SMA and broader neuromuscular disease programs, these filings offer primary-source insight into clinical progress, regulatory interactions, financing plans, and overall corporate strategy.
Scholar Rock Holding Corp's chief scientific officer, Mo Qatanani, reported an automatic sale of company stock related to equity compensation. On January 16, 2026, Qatanani sold 8,406 shares of common stock at an average price of $44.4777 per share. According to the footnotes, this was a mandatory "sell to cover" transaction to satisfy tax withholding obligations arising from the vesting of restricted stock units on January 15, 2026, rather than a discretionary trade.
After this transaction, Qatanani beneficially owned a total of 100,558 equity-based units, consisting of 14,898 shares of common stock and 85,660 restricted stock units that are fully vested.
Scholar Rock Holding Corp’s Chief Human Resources Officer, Caryn Parlavecchio, reported a required tax-related sale of company stock. On January 16, 2026, she sold 6,600 shares of common stock at an average price of $44.4777 per share to cover tax withholding triggered by the vesting of restricted stock units on January 15, 2026. The filing notes this was a mandatory “sell to cover” transaction under the company’s equity incentive plans, not a discretionary trade. After the sale, she beneficially owned 148,864 equity interests, consisting of 78,283 shares of common stock and 70,581 RSUs.
Scholar Rock Holding Corp’s chief medical officer, Jing L. Marantz, sold 5,798 shares of common stock on January 16, 2026 at $44.4777 per share. The filing explains this sale was required to cover tax withholding from the vesting of restricted stock units (RSUs) on January 15, 2026 under the company’s equity incentive plans, and it was not a discretionary trade.
These shares relate to RSU awards granted on February 12, 2024. After the tax-related sale, Marantz beneficially owns 95,687 shares, consisting of 24,974 shares of common stock and 70,713 RSUs. Each RSU is fully vested and represents the right to receive one share of Scholar Rock common stock.
Scholar Rock Holding Corp’s general counsel, Junlin Ho, reported a small insider stock sale tied to restricted stock unit (RSU) vesting. On January 16, 2026, Ho sold 8,016 shares of common stock at an average price of $44.4777 per share.
According to the filing, this sale was mandated under the company’s equity incentive plans solely to cover tax withholding obligations from RSUs that vested on January 15, 2026, and did not represent a discretionary trade. After the transaction, Ho beneficially owned 214,553 equity-linked interests, consisting of 121,471 shares of common stock and 93,082 RSUs, all tied to fully vested awards.
Scholar Rock Holding Corp’s chief scientific officer, Mo Qatanani, reported option exercises and a share sale in company stock. On January 14, 2026, Qatanani exercised several stock options covering a total of 13,112 shares of common stock at exercise prices of
On the same day, Qatanani sold 13,112 shares of common stock at a weighted average price of
Scholar Rock Holding Corp's Chief Financial Officer Vikas Sinha reported an automatic sale of common stock linked to equity award vesting. On January 13, 2026, he sold 16,755 shares of Scholar Rock common stock at $42.70 per share in a transaction coded "S".
According to the disclosure, the shares were sold solely to cover tax withholding obligations arising from the vesting of performance- and time-based restricted stock units (PSUs) and did not represent a discretionary trade. The vesting relates to awards granted on April 27, 2025, including 50,000 PSUs that vested on January 12, 2026, with additional PSUs scheduled to vest through April 27, 2029 if service and performance conditions are met. Following the transaction, Sinha's equity position consists of 33,245 shares of common stock, 100,000 restricted stock units, and 450,000 PSUs.
Scholar Rock Holding Corp's Chief Operating Officer, R. Keith Woods, reported a sale of common stock that was executed solely to cover taxes on recently vested performance-based restricted stock units (PSUs). On January 13, 2026, he sold 16,746 shares of common stock at $42.70 per share in a mandated "sell to cover" transaction under the company’s equity incentive plans, rather than a discretionary trade.
These shares relate to PSU awards granted on April 27, 2025, with 50,000 PSU shares vesting on January 12, 2026 and additional tranches scheduled through April 27, 2029 if service and performance conditions are met. After the tax-related sale, Woods has beneficial ownership of 583,254 share-based interests, consisting of 33,254 shares of common stock, 100,000 time-based RSUs and 450,000 PSUs.
Scholar Rock Holding Corp director and President of R&D Akshay Vaishnaw reported a mandatory tax-related share sale. On 01/13/2026, he sold 20,438 shares of common stock at $42.70 per share in a transaction coded "S." According to the notes, this was a "sell to cover" sale required to satisfy tax withholding from vesting performance- and time-based restricted stock units (PSUs), and is not a discretionary trade.
After the transaction, he beneficially owned 595,767 common share equivalents. This consists of 45,767 shares of common stock, 100,000 restricted stock units, and 450,000 PSUs that vest over time and based on Scholar Rock’s stock price performance, with unvested PSUs forfeited if not vested by April 27, 2029.
Scholar Rock Holding Corp Chief Executive Officer and director David Hallal reported a mandatory share sale linked to equity award vesting. On 01/13/2026, he sold 57,450 shares of common stock at $42.7 per share, solely to cover tax withholding arising from the vesting of performance- and time-based restricted stock units (PSUs) under the company’s equity incentive plans. The transaction was executed as a required “sell to cover” through a designated broker and is noted as not being a discretionary trade.
The vested shares relate to PSU awards granted on April 27, 2025, with 125,000 shares vesting on January 12, 2026, another 125,000 scheduled to vest on April 27, 2027, and additional tranches tied to future stock price and service-based conditions through April 27, 2029, after which any unvested PSUs are forfeited. Following the reported sale, Hallal directly holds 1,541,645 shares of common stock, and a further 205,000 shares are held indirectly by the Hallal Family Irrevocable Trust – 2012, where his spouse serves as trustee and beneficial ownership is disclaimed except for any pecuniary interest.
Scholar Rock Holding Corporation reported preliminary financial and business updates, including an estimated unaudited cash, cash equivalents and marketable securities balance of approximately $365 million as of December 31, 2025. The company has not yet finalized its full fourth-quarter and full-year 2025 results, and the ongoing audit could change these preliminary figures.
The company also issued a press release with business updates and more detail on its 2026 strategic priorities, furnished as Exhibit 99.1, and prepared a corporate presentation for meetings at the 44th Annual J.P. Morgan Healthcare Conference, filed as Exhibit 99.2. The update includes forward-looking statements about its growth strategy, clinical programs, regulatory timelines, commercial launch expectations, a cash runway into 2027, and other operational milestones, all subject to risks outlined in its most recent quarterly report.
FAQ
What is the current stock price of Scholar Rock Holding (SRRK)?
What is the market cap of Scholar Rock Holding (SRRK)?
